Low-Cost High-Speed Train Connecting Valencia and Madrid From RENFE and AVLO

High-Speed Train Connecting Valencia and Madrid from RENFE and Avlo. Launching on 21 February, ticket sales are to start as soon as 20 January. Daniel Hazelhoff reports…

AVLO rolls into Valencia on 21 February, saving potentially millions of commuters substantial amounts on their commute costs. AVLO is a low-cost rail service from RENFE, and the high-speed rail will be connecting Valencia and Madrid. The initial start date, previously reported by Valencia Life, was set for sometime around spring 2022. So the update comes as very welcome news for commuters. Valencia and Madrid connections will finally have a more affordable high-speed railway connection. Tickets start at €7. However, tickets may cost up to €65 at peak times and include comfort add-ons. 

Connections will run regularly, with six per day, creating fluid access from Valencia to Madrid. These six connections supply a grand total of 2,200 possible commuters a day. The trains use a one-class system, so no luxurious first-class amenities will be on offer. Commuters can buy add-ons to increase their comforts, such as extra space, seating choice, and additional luggage. The basic ticket includes one suitcase and one item of handheld luggage. Access to ticket changes and cancellations seem to be an add-on purchase. 

Children under 14 years will have a base ticket of €5, as long as an adult ticket is purchased alongside it, with a maximum of two adult tickets per child. Large families can benefit from a 20% discount, and a 50% discount for large families that fit under the ‘special’ category, meaning five children or more.

Low-cost high-speed train connecting Valencia and Madrid

Four of the six trains will call at Cuenca Fernando Zóbel and Requena-Utiel. The first train departs from Valencia at 09.28, the second at 16.15, and the third at 21.10. From Madrid, the first train departs at 06.30, the second at 12.40 and the final departure leaves at 18.40. All in addition to the 30 already provided by AVE. The quickest connection takes 1 hour and 35 minutes, according to mitma.gob.es.  

Avlo will connect Valencia and Madrid with the highest standard of sanitation and health safety certifications. Health and safety protocols certified by AENOR and SGS will make sure all aspects of cleanliness, disinfection, and COVID safety regulations are in place. This double certification guarantees Avlo and Ave commuters a safe and clean travel environment, according to Las Provincias.

Train Connecting Valencia and Madrid
Comfort class: The interior of an Avlo train

Commuters have long awaited affordable and accessible high-speed commutes from Valencia to Madrid. According to Europa Press, 2021 saw 1.4 million commutes between Valencia and Madrid. The demand is clearly there, and this opportunity provides a platform for those commuters to have easier, more affordable access to the connection. 

The pandemic has slowed down travel, and it has affected almost every industry under the sun. What it hasn’t affected is society’s need for work, and therefore, travel. Hope is on the horizon and high-speed low-cost train lines are here to meet that demand. This new one will connect Valencia and Madrid. It is not yet clear whether other routes will follow, such as to Barcelona. But watch this space for updates.

3 thoughts on “Low-Cost High-Speed Train Connecting Valencia and Madrid From RENFE and AVLO

  1. Aromatase Inhibitors in Men: Effects and Treatment Options

    Aromatase Inhibitors in Men: Effects and Therapeutic Options

    Written by Willem de Ronde and Frank H de Jong

    Abstract

    Aromatase inhibitors (AIs) are drugs that block the enzyme
    aromatase, which converts testosterone into estrogen.
    While initially developed for use in women, AIs are now being explored
    for their potential benefits in men. This article discusses the effects of AIs on hormone
    levels, metabolism, and various therapeutic applications in men.

    Background

    Estrogens play a crucial role in male physiology, particularly in bone health, brain function, and metabolic regulation. Aromatase is responsible for the conversion of testosterone to estrogen, and its activity varies significantly among individuals.

    Metabolism of estrogens in men

    In men, aromatase produces estradiol, which
    is essential for maintaining metabolic and bone health.
    Dysregulation of aromatase can lead to conditions such as osteoporosis or obesity.

    Phenotype of aromatase deficiency and excess

    Aromatase deficiency is rare but can result in hypogonadism, while excess activity may contribute to estrogen-related conditions such as
    breast cancer.

    Aromatase inhibitors

    Aromatase inhibitors are drugs that block the enzyme’s activity, thereby reducing estrogen levels.
    They have shown promise in treating hormone-sensitive cancers and metabolic
    disorders.

    Effects of aromatase inhibition on luteinizing hormone release
    and testosterone production

    Aromatase inhibitors can increase luteinizing hormone (LH) levels, which may enhance
    testosterone production.

    Effects of aromatase inhibition in obese men

    In obese individuals, AIs may improve metabolic markers and reduce visceral
    fat.

    Effects of aromatase inhibition on release of follicle-stimulating hormone and spermatogenesis

    Aromatase inhibitors may impact spermatogenesis, with potential effects on fertility.

    Effects of aromatase inhibition on bone metabolism and epiphysial closure

    AIs may influence bone health, with potential benefits
    for conditions like osteoporosis.

    Effects of aromatase inhibition on male breast

    The impact of AIs on male breast health is
    an area of ongoing research.

    Safety and concerns for aromatase inhibitors in men

    Aromatase inhibitors may cause side effects such as hot flashes,
    bone loss, and cardiovascular risks.

    Conclusion

    Aromatase inhibitors hold promise for treating various conditions in men but require further research
    to fully understand their benefits and risks.

    Competing interests

    The authors declare no competing interests.

    Authors’ contributions

    Willem de Ronde and Frank H de Jong contributed to the article’s concept and writing.

    Contributor Information

    Both authors are researchers in the field of endocrinology.

    References

    Reference 1

    Reference 2

    Reference 3

    ACTIONS

    PERMALINK

    RESOURCES

    Similar articles

    Cited by other articles

    Links to NCBI Databases

    Cite

    Add to Collections

    Feel free to visit my website: how to get a prescription for Steroids

Leave a Reply

Your email address will not be published. Required fields are marked *